NCT06208280View on ClinicalTrials.gov

F01 in the Treatment of Autoimmune Diseases

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 9, 2024

Primary Completion Date

January 31, 2025

Study Completion Date

December 31, 2025

Conditions
Autoimmune Diseases
Interventions
DRUG

After preconditioning with Fludarabine and Cyclophosphamide, F01 will be evaluated.

"Drug: After preconditioning with Fludarabine and Cyclophosphamide, F01 will be evaluated.~Biological: 0.5-3×10\^9 CAR+NK Cells, Treatment follows a lymphodepletion Drug: Fludarabine: 25-30 mg/m\^2 (D-5\~D-3) Drug: Cyclophosphamide: 250-300 mg/ m\^2 (D-5\~D-3)"

Trial Locations (1)

200001

RECRUITING

Department of Rheumatology, Ren Ji Hospital South Campus, School of Medicine, Shanghai JiaoTong University, Shanghai

All Listed Sponsors
collaborator

Shanghai Simnova Biotechnology Co.,Ltd.

INDUSTRY

lead

RenJi Hospital

OTHER